NetworkNewsBreaks – Arcus Biosciences, Inc. (NYSE: RCUS) Featured in Mizuho Securities Research Report
Arcus Biosciences, Inc. (NYSE: RCUS) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We see Taiho's option to exercise zimberelimab (AB122) for development in Japan and other Asian territories (excluding China), disclosed this morning, as a validating event for this candidate, and highlights the strategic value of combining proprietary candidates such as AB928, already licensed by Taiho, with an own checkpoint inhibitor. With the in-licensing of zimberelimab we see the opportunity for Taiho to exercise additional licenses such as AB680 (CD73) and AB154 (TIGIT). We continue to believe that 2020 will…







